A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

~84 mi. (Lóbrega, Spain, +84 more cities)

Site ES34004

CLDN18 Expression

Pancreatic Adenocarcinoma

gemcitabine, +2 more drugs

chemotherapy, +1 more type

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~91 mi. (El Palmar, Spain, +356 more cities)

Hospital Clínico Universitario Virgen de la Arrixaca

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~91 mi. (El Palmar, Spain, +172 more cities)

Hospital Universitario Virgen de la Arrixaca

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC

~91 mi. (El Palmar, Spain, +35 more cities)

Novartis Investigative Site

FOLH1 Expression

Prostate Adenocarcinoma

androgen receptor-directed therapy, +2 more drugs

hormone therapy, +2 more types

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

~91 mi. (El Palmar, Spain, +32 more cities)

Novartis Investigative Site

BCR-ABL1 Fusion, +1 more biomarker

Chronic Myeloid Leukemia

asciminib

targeted therapy

177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

~91 mi. (El Palmar, Spain, +41 more cities)

Novartis Investigative Site

Prostate Adenocarcinoma

lutetium Lu 177 vipivotide tetraxetan

radiation therapy, +1 more type

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

~91 mi. (El Palmar, Spain, +88 more cities)

Hospital Universitario Virgen de la Arrixaca HUVA

FGFR2 Fusion

Intrahepatic Cholangiocarcinoma

futibatinib

targeted therapy

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

~91 mi. (El Palmar, Spain, +23 more cities)

Hospital Universitario de la Arrixaca

HRAS Mutation

Non-Small Cell Lung Carcinoma, +1 more condition

tipifarnib

targeted therapy

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

~91 mi. (El Palmar, Spain, +13 more cities)

Hospital Clínico Universitario Virgen de la Arrixaca

ER Negative, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

~98 mi. (Elche, Spain, +127 more cities)

Hospital General Universitario de Elche

BRAF V600E

Colorectal Carcinoma

cetuximab, +3 more drugs

chemotherapy, +1 more type

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

~98 mi. (Elche, Spain, +260 more cities)

Hospital General Universitario de Elche; Servicio de Oncologia

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

~98 mi. (Elche, Spain, +105 more cities)

Hospital General Universitario de Elche ( Site 1155)

Colorectal Adenocarcinoma

bevacizumab, +1 more drug

targeted therapy